US equities |
META $642.62 ▲+0.00% MU $877.55 ▲+0.00% TSLA $372.22 ▲+0.00% SPCX $147.49 ▲+0.00% NVDA $210.96 ▲+0.00% SNDK $1,238.03 ▲+0.00% NU $15.16 ▲+0.00% CRWV $54.23 ▼-0.01%
FinancialContent

Keros Therapeutics, Inc. - common stock (NQ:KROS)

11.28 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Keros Therapeutics, Inc. - common stock

News headline image
KEROS ALERT: Bragar Eagel & Squire, P.C. is Investigating Keros Therapeutics, Inc. on Behalf of Keros Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Keros Therapeutics, Inc. (KROS)
From Kirby McInerney LLP
Via Business Wire
News headline image
Keros Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - KROS
Via ACCESSWIRE
News headline image
Shareholders that lost money on Keros Therapeutics, Inc.(KROS) should contact Levi & Korsinsky about Securities Fraud Investigation - KROS
Via ACCESSWIRE
Keros Therapeutics Inc. (NASDAQ: KROS) Near the Top of Equities by Percentage Gain on 1/4
Via Investor Brand Network
News headline image
Levi & Korsinsky Announces an Investigation on Behalf of Keros Therapeutics, Inc. (KROS) Shareholders Who May Have Been Affected by Fraud
Via ACCESSWIRE
BioMedNewsBreaks – Keros Therapeutics Inc. (NASDAQ: KROS) Presents Clinical and Preclinical Data from Its Lead Hematological Programs at 64th ASH Event
Via Investor Brand Network